Analyzing Current Trends With Antibody Formats, Payloads, Linkers & Conjugation Technologies to Explore Future Areas of Innovation

• Evaluating innovations in antibody formats and novel conjugates to bolster the success of tumor targeting
• Examining advances in payloads and linkers to improve potency and stability
• Investigating emerging conjugation technologies for efficient manufacturing of ADCs

Speakers:

Gerold Meinhardt

Vice President, Head Global Team Leads, Early Oncology

Daiichi Sankyo